Equities research analysts at CIBC began coverage on shares of Organogenesis (NASDAQ:ORGO) in a report released on Wednesday, April 17th, FirstToMarketsRatingsTable reports. The firm set an “outperform” rating and a $11.00 price target on the stock. CIBC’s target price would indicate a potential upside of 56.92% from the company’s previous close.
ORGO has been the topic of several other research reports. BTIG Research assumed coverage on shares of Organogenesis in a research report on Friday, April 12th. They issued a “buy” rating and a $12.00 price objective on the stock. Oppenheimer assumed coverage on shares of Organogenesis in a research note on Wednesday, April 17th. They issued an “outperform” rating and a $11.00 target price for the company. Finally, SunTrust Banks assumed coverage on shares of Organogenesis in a research note on Thursday, April 11th. They issued a “buy” rating and a $11.00 target price for the company. Five research analysts have rated the stock with a buy rating, Organogenesis presently has a consensus rating of “Buy” and an average price target of $10.80.
Shares of ORGO traded down $0.01 during trading hours on Wednesday, reaching $7.01. 74,994 shares of the stock traded hands, compared to its average volume of 58,215. Organogenesis has a 52 week low of $6.28 and a 52 week high of $310.90.
An institutional investor recently bought a new position in Organogenesis stock. California Public Employees Retirement System acquired a new stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 26,936 shares of the company’s stock, valued at approximately $202,000.
Organogenesis Company Profile
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
See Also: Trading Ex-Dividend Strategy
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.